TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Tarsus Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$69.50+1.43 (+2.10%)
Close on Oct 19, 2026
- Market cap
- $3.02B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tarsus Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product sales, net | $451.36M | $180.06M | $14.73M | $0 | – | – | 100.0% | +150.7% |
| License fees and collaboration revenue | $0 | $2.89M | $2.72M | – | – | – | 0.0% | -100.0% |
| License fees | – | – | – | $23.89M | $53.07M | $0 | – | – |
| Collaboration revenue | – | – | – | $1.92M | $3.96M | $0 | – | – |
| License fees and collaboration revenue | – | $2.89M | $2.72M | $25.82M | – | – | – | – |
| License And Collaboration, Other | – | – | $200.00K | $0 | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Tarsus Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.